23 results
Thumbnail

D2. 259 - A Comprehensive Decision Algorithm for Hypersensitivity Reactions to Iodinated Contrast Media in a Tertiary Care Setting

Thumbnail

D2.255 - NSAID Hypersensitivity Records: Assessing Documentation Practice, Challenges, and Areas for Improvement

Thumbnail

D2.256 - Cytokine release reaction after subcutaneous daratumumab

Thumbnail

D2.246 - Anaphylaxis to sugammadex in a 15 year-old-girl

Thumbnail

D2.247 - Sensitization to Meloxicam, Celecoxib and Paracetamol in patients intolerant to non-steroidal antiinflamatory drugs (NSAIDS)

Thumbnail

D2.248 - Allergy to quinolones: a clinical case

Thumbnail

D2.249 - Application of Desensitization Protocol with Rituximab in the Treatment of Corticosteroid-Dependent Nephrotic Syndrome in an Adolescent

Thumbnail

D2.250 - Can drug allergy develop in x-linked agammaglobulinemia (xla)? case report

Thumbnail

D2.251 - Anaphylaxis due to Andrographis panniculata - an emerging problem

Thumbnail

D2.252 - Confirmation of selectivity pattern to Non-Steroidal Anti-inflammatory Drugs: a retrospective study in a Central Hospital

Thumbnail

D2.253 - Is it possible to treat DRESS without systemic corticosteroids?

Thumbnail

D2.254 - Can a medication leave its mark on the skin?

Thumbnail

D2.257 - Anaphylaxis with FOLFOX scheme: not everything is Oxaliplatin

Thumbnail

D2.258 - Fixed drug eruption caused by co-amoxiclav

Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Thumbnail

D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy